logo

Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation

Cision Canada5 hours ago
Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally
SEATTLE, Aug. 4, 2025 /CNW/ -- The Gates Foundation today announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women's health. It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries.
"For too long, women have suffered from health conditions that are misunderstood, misdiagnosed, or ignored," said Dr. Anita Zaidi, president of the Gates Foundation's Gender Equality Division. "We want this investment to spark a new era of women-centered innovation—one where women's lives, bodies, and voices are prioritized in health R&D."
Women's health R&D remains chronically underfunded. Areas such as gynecological and menstrual health, obstetric care, contraceptive innovation, sexually transmitted infections (STIs) solutions (including HIV PrEP for women), and maternal health and nutrition receive limited investment. According to a 2021 analysis, led by McKinsey & Company, just 1% of healthcare research and innovation is invested in female-specific conditions beyond oncology. Critical issues like preeclampsia, gestational diabetes, heavy menstrual bleeding, endometriosis, and menopause, which together affect hundreds of million women, remain deeply under-researched.
"Investing in women's health has a lasting impact across generations. It leads to healthier families, stronger economies, and a more just world," said Bill Gates, chair of the Gates Foundation. "Yet women's health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change. But we can't do it alone."
To close persistent gaps in funding and research, the foundation is urging governments, philanthropists, investors, and the private sector to co-invest in women's health innovations, help shape product development, and ensure access to treatments for the women and girls who need them most.
"This is the largest investment we've ever made in women's health research and development, but it still falls far short of what is needed in a neglected and underfunded area of huge human need and opportunity," said Zaidi. "Women's health is not just a philanthropic cause—it's an investable opportunity with immense potential for scientific breakthroughs that could help millions of women. What's needed is the will to pursue and follow through."
The foundation's investment will advance innovation across five high-impact areas of a woman's lifespan:
Obstetric care and maternal immunization: Making pregnancy and delivery safer
Maternal health and nutrition: Supporting healthier pregnancies and newborns
Gynecological and menstrual health: Advancing tools and research to better diagnose, treat, and improve gynecological health and reduce infection risk
Contraceptive innovation: Offering more accessible, acceptable, and effective options
Sexually transmitted infections (STIs): Improving diagnosis and treatment to reduce disproportionate burdens on women
Areas of breakthrough potential include research into the vaginal microbiome, first-in-class therapeutics for preeclampsia, and non-hormonal contraception. Included in the commitment are investments that will support data generation and advocacy to help ensure product uptake and impact upon approval.
The five priority areas were selected based on a combination of data and evidence about where innovation can save and improve the most lives, direct insights from women in low- and middle-income countries about their needs and preferences, and the persistently high rates of misdiagnosis caused by gaps in medical knowledge and training. They also reflect the unique challenges faced in low-resource settings, making these areas especially ripe for broader public and private investment to drive meaningful, scalable impact.
"We see the consequences of underinvestment in women's health innovation every day when women suffer needlessly, and sometimes lose their lives, because of the gaps in how we understand and treat conditions that uniquely affect them," said Dr. Bosede Afolabi, professor of obstetrics and gynecology at the College of Medicine, University of Lagos. "This commitment brings much-needed attention to the health challenges women face in places where resources are most limited and the burden is highest. It reflects a recognition that women's lives—and the innovations that support them—must be prioritized everywhere."
By addressing long-standing gaps in women's health, the investment aims to unlock broader social and economic gains. Research shows that every $1 invested in women's health yields $3 in economic growth, and closing the gender health gap could boost the global economy by $1 trillion per year by 2040.
This work supports the foundation's long-term goals through 2045: helping to end preventable deaths of moms and babies; ensuring the next generation grows up without having to suffer from deadly infectious diseases; and lifting millions of people out of poverty, putting them on a path to prosperity. It builds on a 25-year legacy of advancing maternal and child health and supporting women's empowerment globally. The R&D commitment complements the foundation's work supporting the scale-up and delivery of women's health commodities, vaccines such as the HPV vaccine, and child health.
About the Gates Foundation
Guided by the belief that every life has equal value, the Gates Foundation works to help all people lead healthy, productive lives. In developing countries, we work with partners to create impactful solutions so that people can take charge of their futures and achieve their full potential. In the United States, we aim to ensure that everyone—especially those with the fewest resources—has access to the opportunities needed to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill Gates and our governing board.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation
Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation

Cision Canada

time5 hours ago

  • Cision Canada

Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation

Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally SEATTLE, Aug. 4, 2025 /CNW/ -- The Gates Foundation today announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women's health. It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries. "For too long, women have suffered from health conditions that are misunderstood, misdiagnosed, or ignored," said Dr. Anita Zaidi, president of the Gates Foundation's Gender Equality Division. "We want this investment to spark a new era of women-centered innovation—one where women's lives, bodies, and voices are prioritized in health R&D." Women's health R&D remains chronically underfunded. Areas such as gynecological and menstrual health, obstetric care, contraceptive innovation, sexually transmitted infections (STIs) solutions (including HIV PrEP for women), and maternal health and nutrition receive limited investment. According to a 2021 analysis, led by McKinsey & Company, just 1% of healthcare research and innovation is invested in female-specific conditions beyond oncology. Critical issues like preeclampsia, gestational diabetes, heavy menstrual bleeding, endometriosis, and menopause, which together affect hundreds of million women, remain deeply under-researched. "Investing in women's health has a lasting impact across generations. It leads to healthier families, stronger economies, and a more just world," said Bill Gates, chair of the Gates Foundation. "Yet women's health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change. But we can't do it alone." To close persistent gaps in funding and research, the foundation is urging governments, philanthropists, investors, and the private sector to co-invest in women's health innovations, help shape product development, and ensure access to treatments for the women and girls who need them most. "This is the largest investment we've ever made in women's health research and development, but it still falls far short of what is needed in a neglected and underfunded area of huge human need and opportunity," said Zaidi. "Women's health is not just a philanthropic cause—it's an investable opportunity with immense potential for scientific breakthroughs that could help millions of women. What's needed is the will to pursue and follow through." The foundation's investment will advance innovation across five high-impact areas of a woman's lifespan: Obstetric care and maternal immunization: Making pregnancy and delivery safer Maternal health and nutrition: Supporting healthier pregnancies and newborns Gynecological and menstrual health: Advancing tools and research to better diagnose, treat, and improve gynecological health and reduce infection risk Contraceptive innovation: Offering more accessible, acceptable, and effective options Sexually transmitted infections (STIs): Improving diagnosis and treatment to reduce disproportionate burdens on women Areas of breakthrough potential include research into the vaginal microbiome, first-in-class therapeutics for preeclampsia, and non-hormonal contraception. Included in the commitment are investments that will support data generation and advocacy to help ensure product uptake and impact upon approval. The five priority areas were selected based on a combination of data and evidence about where innovation can save and improve the most lives, direct insights from women in low- and middle-income countries about their needs and preferences, and the persistently high rates of misdiagnosis caused by gaps in medical knowledge and training. They also reflect the unique challenges faced in low-resource settings, making these areas especially ripe for broader public and private investment to drive meaningful, scalable impact. "We see the consequences of underinvestment in women's health innovation every day when women suffer needlessly, and sometimes lose their lives, because of the gaps in how we understand and treat conditions that uniquely affect them," said Dr. Bosede Afolabi, professor of obstetrics and gynecology at the College of Medicine, University of Lagos. "This commitment brings much-needed attention to the health challenges women face in places where resources are most limited and the burden is highest. It reflects a recognition that women's lives—and the innovations that support them—must be prioritized everywhere." By addressing long-standing gaps in women's health, the investment aims to unlock broader social and economic gains. Research shows that every $1 invested in women's health yields $3 in economic growth, and closing the gender health gap could boost the global economy by $1 trillion per year by 2040. This work supports the foundation's long-term goals through 2045: helping to end preventable deaths of moms and babies; ensuring the next generation grows up without having to suffer from deadly infectious diseases; and lifting millions of people out of poverty, putting them on a path to prosperity. It builds on a 25-year legacy of advancing maternal and child health and supporting women's empowerment globally. The R&D commitment complements the foundation's work supporting the scale-up and delivery of women's health commodities, vaccines such as the HPV vaccine, and child health. About the Gates Foundation Guided by the belief that every life has equal value, the Gates Foundation works to help all people lead healthy, productive lives. In developing countries, we work with partners to create impactful solutions so that people can take charge of their futures and achieve their full potential. In the United States, we aim to ensure that everyone—especially those with the fewest resources—has access to the opportunities needed to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill Gates and our governing board.

Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First Nanosecond PFA System, Ushering in the PFA 3.0 Era
Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First Nanosecond PFA System, Ushering in the PFA 3.0 Era

Cision Canada

time5 hours ago

  • Cision Canada

Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First Nanosecond PFA System, Ushering in the PFA 3.0 Era

SHENZHEN, China, Aug. 4, 2025 /CNW/ -- Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovative NxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval from China's National Medical Products Administration (NMPA). As the world's first third-generation ns-PFA system utilizing high-voltage nanosecond pulses for pulmonary vein isolation (PVI) in atrial fibrillation (AF) treatment, this breakthrough marks the dawn of the PFA 3.0 era and represents the innovative capabilities of Pulsecare Medical in cardiovascular multimodal therapy. The World's First Commercially Approved Nanosecond PFA PFA has revolutionized AF treatment through its tissue selectivity, safety, and procedural efficiency. Yet, early-generation systems using microsecond pulses face key challenges—excessive muscle stimulation, reliance on general anesthesia, and risks like hemolysis and gas embolism—that limit broad adoption. As the world's first and only commercially available nanosecond PFA system, NxPFA™ represents the "Next of PFA" generation. It combines the MaviPulse™ high repetition frequency ns-PFA console with the InteShot™ basket-shaped catheter to deliver irreversible electroporation of cardiomyocytes via high-voltage nanosecond pulses, effectively overcoming key limitations of microsecond PFA (μs-PFA) technologies: Significantly reduces neuromuscular stimulation, enabling procedures under conscious sedation, improving patient comfort and lowering anesthesia risks; Combines nanosecond pulses with a basket-shaped catheter to ensure optimal electrode-tissue contact and high success rates, while shortening procedural time; Substantially lowers intravascular gas formation, lowering the risk of stroke or systemic embolism; Minimizes erythrocytic damage and post-procedural bilirubin elevation, reducing potential kidney injury. NxPFA™ Demonstrates Outstanding Efficacy and Safety The NxPFA ™ system has been clinically validated through the SCENA-AF multicenter registration trial, which enrolled 166 patients with paroxysmal atrial fibrillation. The data has been acknowledged by NMPA and will soon be published in an academic journal. Key outcomes include: 100% acute pulmonary vein isolation success rate 88.27% one-year treatment success rate (PPS) No device-related serious adverse events reported Over 92.8% of procedures completed under conscious sedation, with excellent intraoperative tolerance. These results confirm NxPFA ™ 's strong performance in efficacy, safety, efficiency, and patient comfort. It remains the only PFA system globally to achieve one-shot PVI under conscious sedation with high success, marking the debut of the third-generation nanosecond PFA era. "NxPFA ™ 's approval is not only a major milestone for Pulsecare Medical but also a transformative breakthrough for cardiac electrophysiology. With NxPFA ™, we address critical clinical challenges and look forward to collaborating with global EP experts to shape the future of arrhythmia treatment—delivering smarter tools to physicians and safer, more effective, more comfortable therapies to patients," said Dr. Javen Tan, CEO of Pulsecare Medical. Founded in July 2021 and headquartered in Shenzhen, Pulsecare Medical is dedicated to the innovation and development of cardiovascular multimodal therapeutic devices. Backed by a rare cross-disciplinary team combining clinical and engineering expertise, the company is building a next-generation energy platform for interventional therapies. Pulsecare offers total solutions for cardiac electrophysiology and hypertension interventional therapy, aiming to lead in minimally and non-invasive treatments.

IMG Announces Ninth Annual 'Leave Your Mark' Grant Opportunity
IMG Announces Ninth Annual 'Leave Your Mark' Grant Opportunity

Cision Canada

time6 hours ago

  • Cision Canada

IMG Announces Ninth Annual 'Leave Your Mark' Grant Opportunity

INDIANAPOLIS, Aug. 4, 2025 /CNW/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is excited to be accepting applications for its annual Leave Your Mark Grant. In its ninth year, the Leave Your Mark initiative is designed to invest in causes addressed by mission and social good organizations around the world. Grant applications will be accepted August 1 through September 12, 2025. IMG will be granting funds to five winners — two mission or social good organizations and three individuals participating in a mission, volunteer, or service trip. The two winning organizations will receive $3,500 each, and the three winning individuals will receive $1,000 each. To apply for IMG's Leave Your Mark Grant, applicants are asked to submit a 500-word essay or 3-minute video that describes why their mission or service trip is important, how they're working to overcome current obstacles facing the world, and how this grant will help support their global outreach efforts. "Each year, we are inspired by the incredible work being done by the individuals and organizations that apply for the Leave Your Mark Grant," said Justin Poehler, IMG Chief Commercial Officer. "This grant opportunity allows us to support those who are making a tangible difference in communities around the world, and we're proud to continue this tradition for the ninth year." Mission of Hope, a 2024 winning organization of the Leave Your Mark Grant, used the funds to support their nutrition program in Haiti and provided meals to 350 children for an entire year. GAIA Vaccine Foundation, the second 2024 winning organization, used the funds to provide free HIV testing to more than 1,000 expectant mothers in West Africa. The 2024 individual winners used their funds to support several initiatives including farming education in Kenya, religious mission work along the Amazon River, and care for orphaned children with disabilities in Ukraine. To apply for this year's Leave Your Mark Grant, visit The deadline for all applications is September 12, 2025, and winners will be announced October 16, 2025. About IMG® (International Medical Group®) IMG® (International Medical Group®), a SiriusPoint company, is an award-winning global insurance benefits and assistance services company that has served millions of members worldwide since its founding in 1990. The preeminent provider of travel and health safety solutions, IMG offers a wide range of insurance programs, including international private medical insurance, travel medical insurance, and travel insurance, as well as enterprise services, including insurance administrative services and 24/7 emergency medical, security, and travel assistance. IMG's world-class services, combined with an extensive product portfolio, provide Global Peace of Mind® for travelers, students, missionaries, marine crews, and other individuals or groups traveling, working, or living away from home. For more information, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store